Ulla Kristina Laakso, MD
Psychiatry · New York, NYNPI 1598841371
Payments from drug & device makers
Across 3,261 payments — averaging $273.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$198K
- Alkermes, Inc.$196K
- AbbVie$102K
- Teva Pharmaceuticals USA, Inc.$82K
- Vanda Pharmaceuticals Inc.$78K
- Axsome Therapeutics, Inc.$48K
- plus $187K from 30 others
What the payments were for
- Consulting fees$74,8628%
- Speaking & faculty fees$686,83977%
- Travel & lodging$56,9996%
- Food & beverage$71,1058%
- Education$4920%
- Gifts$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$385,433
- LYBALVI$381,237
- ABILIFY MAINTENA$98,524
- VRAYLAR$94,501
- ARISTADA INITIO$84,588
- Fanapt$75,119
- REXULTI$62,002
- AUSTEDO$49,066
- Auvelity$46,009
- ABILIFY MYCITE$35,165
- ABILIFY ASIMTUFII$34,873
- QELBREE$34,032
- INGREZZA$25,888
- Quillichew ER$20,141
- Quillivant$20,141
- Dyanavel XR$20,141
- CAPLYTA$19,232
- COBENFY$18,341
- UZEDY$16,608
- QUVIVIQ$15,867
How this compares
$890,304 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 43 | $385,415 |
| LybalviOlanzapine/Samidorphan Malate | 120 | $187,227 |
| RexultiBrexpiprazole | 34 | $60,324 |
| Abilify MaintenaAripiprazole | 12 | $50,656 |
| Seroquel XrQuetiapine Fumarate | 22 | $27,015 |
| VraylarCariprazine Hcl | 20 | $23,355 |
| CaplytaLumateperone Tosylate | 14 | $21,660 |
| BelsomraSuvorexant | 38 | $15,955 |
| Depakote ErDivalproex Sodium | 20 | $14,726 |
| EquetroCarbamazepine | 26 | $10,003 |
| Lurasidone Hcl | 20 | $9,702 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 201 | $8,930 |
| QuviviqDaridorexant Hcl | 20 | $8,791 |
| Divalproex Sodium ErDivalproex Sodium | 195 | $8,700 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $7,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $82,054 | $385,41543 claims |
| Alkermes, Inc.Lybalvi | $195,935 | $187,227120 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $197,544 | $110,98046 claims |
| AbbVieVraylar | $101,948 | $23,35520 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $21,595 | $21,66014 claims |
| MerckBelsomra | $138 | $15,95538 claims |
| Validus Pharmaceuticals LLCEquetro | $10,174 | $10,00326 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $16,782 | $8,79120 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $903 | $7,59118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.